Table 1.
Joint effects survival analysis of clinical features and the prognostic signature with OS in HCC patients
| Group | Risk Score | Variables | Events/total(n=370) | MST (days) | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI) | Adjusted P£ |
|---|---|---|---|---|---|---|---|---|
| Tumor Stage c | ||||||||
| A | Low risk | Stage I | 17/106 | 2532 | 1 | 1 | ||
| B | Low risk | Stage II | 7/34 | 3258 | 1.273(0.527-3.075) | 0.592 | 1.283(0.531-3.104) | 0.58 |
| C | Low risk | Stage III+IV | 13/33 | 1622 | 2.916(1.416-6.008) | 0.004 | 2.894(1.405-5.936) | 0.004 |
| D | High risk | Stage I | 25/65 | 1372 | 3.473(1.872-6.442) | <0.0001 | 3.446(1.857-6.393) | <0.0001 |
| E | High risk | Stage II | 19/51 | 1149 | 3.853(1.996-7.439) | <0.0001 | 3.812(1.974-7.362) | <0.0001 |
| F | High risk | Stage III+IV | 35/57 | 419 | 6.419(3.577-11.520) | <0.0001 | 5.839(3.211-10.617) | <0.0001 |
| Histological Grade d | ||||||||
| a | Low risk | G1 | 10/39 | 2131 | 1 | 1 | ||
| b | Low risk | G2 | 25/97 | 2456 | 1.045(0.501-2.177) | 0.907 | 1.388(0.563-3.424) | 0.476 |
| c | Low risk | G3+G4 | 7/46 | NA | 0.582(0.221-1.530) | 0.272 | 0.830(0.278-2.476) | 0.738 |
| d | High risk | G1 | 8/16 | 649 | 2.894(1.132-7.398) | 0.026 | 3.186(1.034-9.819) | 0.044 |
| e | High risk | G2 | 35/80 | 931 | 2.923(1.444-5.918) | 0.003 | 3.209(1.318-7.813) | 0.01 |
| f | High risk | G3+G4 | 41/87 | 757 | 2.814(1.406-5.633) | 0.003 | 3.346(1.407-7.962) | 0.006 |
| Serum AFP e | ||||||||
| I | Low risk | ≤400 | 25/118 | 2532 | 1 | 1 | ||
| II | Low risk | >400 | 4/26 | NA | 0.651(0.226-1.873) | 0.426 | 0.544(0.163-1.815) | 0.322 |
| III | High risk | ≤400 | 37/95 | 1271 | 2.735(1.641-4.558) | 0.00011 | 2.702(1.578-4.628) | 0.0003 |
| IV | High risk | >400 | 18/38 | 931 | 2.630(1.427-4.850) | 0.002 | 2.435(1.265-4.688) | 0.008 |
| MVIg | ||||||||
| i | Low risk | NO | 39/168 | 2532 | 1 | 1 | ||
| ii | Low risk | YES | 5/15 | 837 | 1.433(0.715-2.872) | 0.311 | 1.165(0.523-2.5950 | 0.708 |
| iii | High risk | NO | 71/155 | 899 | 3.162(1.878-5.323) | <0.0001 | 3.034(1.742-5.284) | <0.0001 |
| iv | High risk | YES | 12/25 | 1135 | 3.347(1.891-5.925) | <0.0001 | 2.686(1.334-5.407) | 0.006 |
| Child-Pugh score h | ||||||||
| ① | Low risk | A | 24/118 | 3258 | 1 | 1 | ||
| ② | Low risk | B+C | 4/14 | 1624 | 1.582(0.543-4.602) | 0.4 | 1.636(0.560-4.776) | 0.368 |
| ③ | High risk | A | 35/98 | 1372 | 2.713(1.607-4.582) | 0.0002 | 2.635(1.542-4.5030 | 0.0004 |
| ④ | High risk | B+C | 5/8 | 394 | 5.261(1.998-13.856) | 0.001 | 4.825(1.791-13.000) | 0.002 |
| Ishak fibrosis scoreb | ||||||||
| 1 | Low risk | 0 | 14/45 | 2542 | 1 | 1 | ||
| 2 | Low risk | 1/2/3/4/5/6 | 10/72 | NA | 0.510(0.224-1.162) | 0.109 | 0.538(0.225-1.283) | 0.162 |
| 3 | High risk | 0 | 16/29 | 931 | 2.203(1.071-4.523) | 0.032 | 1.903(0.893-4.054) | 0.095 |
| 4 | High risk | 1/2/3/4/5/6 | 24/65 | 1229 | 2.264(1.143-4.485) | 0.019 | 2.640(1.288-5.411) | 0.008 |
| Residual tumorf | ||||||||
| 11 | Low risk | R0 | 24/115 | 2456 | 1 | 1 | ||
| 22 | Low risk | R1+R2+RX | 12/50 | 3258 | 2.696(1.057-6.876) | 0.038 | 2.579(0.904-7.355) | 0.076 |
| 33 | High risk | R0 | 36/91 | 1005 | 3.075(2.074-4.558) | <0.0001 | 2.982(1.946-4.570) | <0.0001 |
| 44 | High risk | R1+R2+RX | 24/58 | 1149 | 4.286(2.235-8.221) | <0.0001 | 3.316(1.558-7.057) | 0.002 |
Notes: b Information of ishak fibrosis score was unavailable in 159 patients; c Information of tumor stage was unavailable in 24 patients; d Information of histological grade was unavailable in 5 patients; e Information of serum AFP was unavailable in 93 patients; f Information of radical resection was unavailable in 7 patients; g Information of micro vascular invasion was unavailable in 56 patients; h Information of Child-Pugh score was unavailable in 132 patients; £Adjusted for tumor stage and radical resection.
Abbreviations: OS, overall survival; HCC, hepatocellular carcinoma; MST, median survival time; HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein; MVI, micro vascular invasion.